FDA AdCom Votes in Favor of Emergency Use Authorization for Pfizer (PFE) and BioNTech's (BNTX) Covid-19 Vaccine in Children 5 to <12 Years

Go back to FDA AdCom Votes in Favor of Emergency Use Authorization for Pfizer (PFE) and BioNTech's (BNTX) Covid-19 Vaccine in Children 5 to <12 Years

Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children Aged 5-11

October 29, 2021 5:46 PM EDT

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has authorized for emergency use the Pfizer-BioNTech COVID-19 Vaccine for children 5 through 11 years of age (also referred to as 5 to... More

US Govt Purchases Additional 50M Doses of Pfizer (PFE) and BioNTech (BNTX) COVID-19 Vaccine

October 28, 2021 6:45 AM EDT

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. government has purchased 50 million more doses of the companies COVID-19 vaccine. The U.S. will receive these additional doses to continue to support preparedness for pediatric vaccinations, including securing vaccines for children under 5 years of age, should they receive regulatory authorization. The companies expect to deliver all these doses by April 30, 2022.

With this order, the U.S. government has... More

Trillium Therapeutics (TRIL) Shareholders Approve Takeover by Pfizer

October 26, 2021 5:15 PM EDT

Trillium Therapeutics Inc. (NASDAQ: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (PF Argentum) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (Pfizer) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than... More

U.S. FDA advisers vote in favor of Pfizer/BioNTech COVID-19 vaccine in young kids

October 26, 2021 4:23 PM EDT

(Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Tuesday voted to recommend the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages five to 11 years.

(Reporting by Manas Mishra in Bengaluru; Editing by Bill Berkrot)

... More

Pfizer (PFE) Covid Shot For Kids Age 5-11 Gets FDA Panel's Backing - Bloomberg

October 26, 2021 4:18 PM EDT

Pfizer (NYSE: PFE) Covid Shot For Kids Age 5-11 Gets FDA Panel's Backing - Bloomberg

... More